

FORWARD thinning/thickening manuscript\_re-submission\_December 2019

**Supplementary Table S2** Change from baseline in cartilage thickness ( $\mu\text{m}$ ) by ordered values at 24 months (mITT Analysis Set)

<b>Ordered Value</b>	<b>Placebo</b>	<b>Sprifermin 100 <math>\mu\text{g}</math> q6mo</b>
<b>Mean (95% CI)</b>	<b>(N=96)</b>	<b>(N=101)</b>
OV1	-199.5 (-242.2, -156.8)	-139.7 (-166.8, -112.5)
OV2	-130.7 (-160.4, -101.1)	-83.0 (-102.0, -64.0)
OV3	-104.7 (-133.3, -76.2)	-50.8 (-65.1, -36.5)
OV4	-80.3 (-106.1, -54.5)	-31.3 (-43.7, -19.0)
OV5	-65.1 (-88.3, -41.9)	-18.0 (-29.3, -6.6)
OV6	-48.4 (-66.9, -29.9)	-5.3 (-16.7, 6.2)
OV7	-32.1 (-48.9, -15.3)	7.2 (-4.5, 18.9)
OV8	-20.4 (-35.1, -5.7)	20.3 (9.1, 31.5)
OV9	-6.8 (-18.4, 4.7)	31.5 (20.3, 42.7)
OV10	6.3 (-3.9, 16.5)	44.0 (32.2, 55.7)
OV11	19.5 (10.3, 28.7)	58.1 (46.0, 70.1)
OV12	31.1 (22.2, 39.9)	73.9 (60.8, 87.1)
OV13	42.2 (32.9, 51.6)	89.6 (75.0, 104.2)
OV14	60.9 (51.0, 70.8)	107.4 (92.7, 122.2)
OV15	80.6 (70.6, 90.6)	132.5 (115.4, 149.6)
OV16	112.7 (101.0, 124.4)	187.6 (163.9, 211.3)

CI, confidence interval; mITT, modified intention-to-treat; OV, ordered value; q6mo, every 6 months active cycle.